Omnicell enters a powerful ten-year refresh cycle
The guest argued that Omnicell is entering the leading edge of a ten-year medication cabinet refresh cycle, which will drive bookings and revenue growth.
The argument
The guest explained that Omnicell operates in a duopoly with Pyxis and locks in customers with ten-year sole-source contracts. The business is shifting toward a more predictable model with 50% to 60% of revenue now recurring, and it benefits from hospital automation trends to reduce medication errors and waste.
The thesis, stress-tested
✓ What validates it
- ✓Acceleration of bookings in mid-to-late current year
- ✓Revenue growth acceleration manifesting in the following fiscal year
▸ Risks discussed
- ▸Lumpy capital cycles that Wall Street historically dislikes
- ▸Potential macro headwinds affecting hospital capital expenditure budgets
Hear it yourself
"So they're they're definitely trying to flatten out some of that volatility in the revenue. And so I think today, roughly 50 to 60% of their revenue is now considered recurring."
00:00 / 00:12
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE